# Cost-per-responder analysis of Tralokinumab versus Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis in the US and Canada

## Jashin J. Wu<sup>1</sup>, Sanjeev Balu<sup>2</sup>, Nikolaj Birk Larsen<sup>3</sup>, Ryan Pulleyblank<sup>3</sup>, Liv Strømkjær<sup>3</sup>, Aron Quah<sup>4</sup>, Marni Wiseman<sup>5,6</sup>

<sup>1</sup>Department of Dermatology, University of Miami Miller School of Medicine, Miami, Florida, United States; <sup>2</sup>LEO Pharma, Madison, USA; <sup>3</sup>NHTA ApS, Copenhagen, Denmark; <sup>4</sup>LEO Pharma, North York, Canada; Section of Dermatology, Department of Medicine, University of Manitoba, Winnipeg, Canada; Wiseman Dermatology Research, Winnipeg, Canada

## **Objectives**

• Applying an indirect comparison of efficacy, we examined the cost-per-responder of tralokinumab compared to dupilumab, both in combination with topical corticosteroids (TCS) for the treatment of moderate-to-serve AD in the United States (US) and Canada.

### Results

Figure 1a. Cost-per-responder EASI-75						
	Tralokinumab		Dupilumab			
	EASI-75	IGA 0/1	EASI-75	IGA 0/1		
Absolute risk reduction	0.477	0.363	0.477	0.257		
Number needed to treat	2.098	2.758	2.098	3.897		


Abbreviations: EASI-75 = Eczema Area and Severity Index improvement of at least 75%; IGA 0/1 = Investigator's Global Assessment of 1 or 0.


#### United states

- For the US, the average cost per EASI-75 responder for tralokinumab Q2W was \$62,714 (Q4W SA 10%: \$61,239; 20%: \$59,763) versus \$63,993 for dupilumab Q2W.
- The average cost per IGA-0/1 responder for tralokinumab Q2W was \$82,419 (Q4W SA 10%: \$80,480; 20%: \$78,450) versus \$118,835 for dupilumab Q2W

#### Canada

- For Canada, the average cost per EASI-75 responder for tralokinumab Q2W was \$22,846 (Q4W SA 10%: \$22,308; 20%: \$21,771) versus \$26,475 for dupilumab Q2W.
- The average cost per IGA-0/1 responder for tralokinumab Q2W was \$30,024 (Q4W SA: 10%: \$29,317; 20%: \$28,611) versus \$49,165 for dupilumab Q2W.





<sup>1</sup>a: Estimated cost-per-responder when considering the EASI-75 response criteria based on the MAIC efficacy data.

## Conclusions

• This analysis indicates that tralokinumab in combination with TCS is associated with lower costs-perresponder compared with dupilumab in combination with TCS in the treatment of moderate-to-severe AD in the US and Canada when assessing EASI-75 and IGA-0/1 response criteria at 32 weeks.

## Background

- Biologic treatments such as tralokinumab and dupilumab are therapeutic options for patients with moderate-to-severe atopic dermatitis (AD) who do not achieve adequate control with topical treatments or phototherapy.
- To date, no trials have been conducted to directly evaluate the relative efficacy of these biologic treatments.

## **Methods**

#### Study design

- A cost-per-responder analysis was undertaken considering the Eczema Area and Severity Index 75 (EASI-75) and Investigator's Global Assessment (IGA-0/1) response criteria over 32 weeks.
- For each treatment, the cost-per-responder was computed by multiplying the treatment cost by the number needed to treat (NNT).
- The model structure is presented in Figure 2.

#### Material

- · Efficacy data were derived from an unanchored matchingadjusted indirect comparison<sup>1</sup> (MAIC) utilizing patient-level data from ECZTRA-3<sup>2</sup> (tralokinumab) and aggregate data from LIBERTY AD CHRONOS (dupilumab)3.
- Treatment cost was defined as the drug cost of the biologic treatment with a duration corresponding to 32 weeks. Cost of TCS was not included. Treatments were assumed to be administered every 2 weeks (Q2W).
- The costs were estimated based on Wholesale Acquisition Costs (WAC) from the US<sup>4</sup> and ex-factory prices via the McKesson price list for Canada<sup>5</sup>. All prices were converted to US dollars (\$).
- Sensitivity analyses (SA) were conducted with every 4 week (Q4W) dosing beginning at week 16 for 10% and 20% of patients treated with tralokinumab.



Abbreviations: ARR = Absolute risk reduction; C = Treatment cost; CPR = Cost-perresponder; NoBiologic = Placebo + topical corticosteroids; NNT = Number needed to treat: R= response rate; T = treatment.

Table 2. Model cost inputs						
	Tralokinumab	Dupilumab				
Unit cost						
Unites states	\$879.06	\$1,793.96				
Canada	\$320.23	\$742.21				
Number of units used for 32 weeks						
Q2W dosing	34	17				
Q4W dosing from week 16	26	N/a				

Note: Canadian prices were converted to US dollars (\$), Q2W dosing were applied for all patients in the base case. Q4W was only applied in sensitivity analysis.

Abbreviations: Q2W = dosed every two weeks; Q4W = dosed every 4 weeks.

#### Table 3. Model clinical inputs

	Tralokinumab	Dupilumab	TCS (+ Placebo)
Response rates at 32 weeks			
EASI-75	0.719	0.719	0.242
IGA 0/1	0.499	0.393	0.136

Note: The tralokinumab and dupilumab response rates were based on an unanchored matched-adjusted indirect comparison. TCS (+ placebo) response rates were derived directly from the ECZTRA-3 trial. Response rates were used to calculate the absolute risk reduction

Abbreviations: Eczema Area and Severity Index improvement of at least 75%: IGA 0/1 = Investigator's Global Assessment of 1 or 0.

## References

- 1) Torres et al., 2023 ISAD Hybrid Meeting'23, Gdansk, Poland.
- 2) Silverberg et al., 2021 <u>https://doi.org/10.1111/bjd.19573</u>
- 2) Blauvet et al., 2017 https://doi.org/10.1016/S0140-6736(17)31191-1
- 4) Medi-Span Price Rx WAC. 2023
- 5) McKesson price list (Ontario) Ex Factory. 2023

## **Disclosures**

Funding for this research has been provided by LEO Pharma A/S, Ballerup, Denmark. JW and MW were clinical consultants/advisors on this study; NL, RP, and LS were consultants on this study and received research funding; SB and AQ are employees of LEO Pharma



Presented at the Fall Clinical Dermatology Conference, October 19-22, 2023 | Las Vegas, Nevada

<sup>1</sup>b: Estimated cost-per-responder when considering the IGA 0/1 response criteria based on the MAIC efficacy data.